Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

09/19/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Johannes Gerardus Christiaan Petrus Schikan

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Pharvaris NV (NASDAQ:PHVS)
Gráfico Histórico do Ativo
De Mar 2025 até Abr 2025

Click aqui para mais gráficos Pharvaris NV.

Pharvaris NV (NASDAQ:PHVS)
Gráfico Histórico do Ativo
De Abr 2024 até Abr 2025

Click aqui para mais gráficos Pharvaris NV.

Notícias Pharvaris NV

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Segunda, 7 de Abril de 2025 (6 dias atrás) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Segunda, 7 de Abril de 2025 (7 dias atrás) • Edgar (US Regulatory)

Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission
Terça, 1 de Abril de 2025 (2 semanas atrás) • GlobeNewswire Inc.

Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress
Segunda, 3 de Março de 2025 (1 mês atrás) • GlobeNewswire Inc.

Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025
Segunda, 3 de Março de 2025 (1 mês atrás) • GlobeNewswire Inc.

Pharvaris Outlines 2025 Strategic Priorities
Segunda, 13 de Janeiro de 2025 (3 meses atrás) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Segunda, 2 de Dezembro de 2024 (4 meses atrás) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Quarta, 13 de Novembro de 2024 (5 meses atrás) • Edgar (US Regulatory)

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
Quarta, 13 de Novembro de 2024 (5 meses atrás) • GlobeNewswire Inc.

Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
Terça, 12 de Novembro de 2024 (5 meses atrás) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Quinta, 31 de Outubro de 2024 (5 meses atrás) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Quinta, 24 de Outubro de 2024 (6 meses atrás) • Edgar (US Regulatory)

Mais Notícias de Pharvaris NV

Argonomics (PK)

Golden Triangle Ventures (PK)

Jpmorgan Chase Financial...

AS IP Tech (CE)

Exchange Traded

XS2828686951 20260116 0....

NASDAQ Biotechnology

Regent Ventures

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições